2006 Annual Session

2008 Topics

	Additional Topics
	Associates, Residents and Fellows in Training
	Cardiology
	Career and Professionalism
	Clinical Pearls
	Computer in Practice
	Clinical Pharmacology
	Ethics and Health Policy
	Endocrinology
	Gastroenterology and Hepatology
	Health Issues Related to Age and Gender
	Hematology
	Hospital Medicine
	Infectious Diseases
	Medical Practice Management
	Multiple Small Feedings of the Mind
	Nephrology and Hypertension
	Neurology
	Oncology
	Ophthalmology and Otolaryngology
	Perioperative Medicine
	Pre-Session Courses
	Psychiatry
	Pulmonary Diseases and Critical Care
	Rheumatology and Allergy & Immunology
	Updates

Chronic Kidney Disease: The New Silent Killer Part I (Presented in Cooperation with the American Society of Nephrology)

Session #: 856-200
Presenter(s): Stuart M. Sprague, DO, Member; Patrick S. Parfrey, MD, FACP; Jonathan Himmelfarb, MD; Mark E. Rosenberg, MD; Robert G. Narins, MD, MACP; Derrick L. Latos, MD, MACP
Session Length: 1:00 hr
Event: 2006 ACP Annual Session
Date: April 6-8, 2006

Purchase Media - Session #: 856-200
Description	Price	Qty.	Cart
CD	$17.00		buy now
MP3	$17.00		buy now
iPod Audio	$17.00		buy now

1. What are the major etiologies and stages of CKD?
2. What clinical indicators determine how to use vitamin D, calcimimetic drugs, and phosphate-binding agents in CKD?
3. How does renal damage adversely affect atherosclerosis?
4. How does the management of diabetes affect the course of CKD?
5. Are all antihypertensive drugs equally effective in CKD?
6. What are the indications for considering vascular access and transplantation evaluation?

About